---
title: "Lifeon Pharmaceutical: Methylphenidate Hydrochloride Extended-Release Tablets are expected to be launched by the end of the third quarter of this year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/238829648.md"
description: "Lifeon Pharmaceutical stated on the Shenzhen Stock Exchange interactive platform that methylphenidate hydrochloride sustained-release tablets are expected to be launched by the end of the third quarter of this year. During the period between approval and launch, a relatively complete commercialization plan and preparations will be made, and work such as market access, hospitalization, and professional promotion will be implemented as planned. Methylphenidate hydrochloride sustained-release tablets use advanced three-layer osmotic pump controlled-release technology to achieve rapid onset through precise controlled release, effectively maintaining stable efficacy throughout the day, consistent with the \"Focus Da\" formulation technology"
datetime: "2025-05-06T03:55:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/238829648.md)
  - [en](https://longbridge.com/en/news/238829648.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/238829648.md)
generator: "portal-rs"
---

# Lifeon Pharmaceutical: Methylphenidate Hydrochloride Extended-Release Tablets are expected to be launched by the end of the third quarter of this year

Lifeon Pharmaceutical stated on the Shenzhen Stock Exchange interactive platform that methylphenidate hydrochloride sustained-release tablets are expected to be launched by the end of the third quarter of this year. During the period between approval and launch, a relatively complete commercialization plan and preparations will be made, and work such as market access, hospital admission, and professional promotion will be implemented as planned. Methylphenidate hydrochloride sustained-release tablets utilize advanced three-layer osmotic pump controlled-release technology to achieve rapid onset through precise controlled release, effectively maintaining stable efficacy throughout the day, consistent with the "Focus Da" formulation technology

### Related Stocks

- [003020.CN](https://longbridge.com/en/quote/003020.CN.md)

## Related News & Research

- [My Mountain Mover Recognized Among the 2026 Inc. 5000 Fastest-Growing U.S. Companies](https://longbridge.com/en/news/297087696.md)
- [08:39 ETPredoc Launches Curated Data Layer to Make Fragmented Medical Records Usable](https://longbridge.com/en/news/297187951.md)
- [Haisco Enters Into Exclusive License Agreement With New US Venture Founded By Population Health Partners And ARCH Venture Partners](https://longbridge.com/en/news/296910145.md)
- [RCS - ZAGENO - ZAGENO and ORO Labs Partnership](https://longbridge.com/en/news/297046609.md)
- [Northstar Clean Tech wins new US patent for asphalt shingle reprocessing technology](https://longbridge.com/en/news/297153537.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**